BC Week In Review | Jun 9, 2017
Clinical News

Endocyte stops enrollment in Phase Ia/Ib solid tumor trial of EC1456

Endocyte Inc. (NASDAQ:ECYT) will stop enrollment in the Phase Ib portion of an open-label, U.S. Phase Ia/Ib trial of twice-weekly 6 mg/m 2 EC1456 in up to 40 folate receptor-positive non-small cell lung cancer (NSCLC)...
BC Week In Review | Mar 9, 2015
Clinical News

EC1456: Phase I data

Data from 16 evaluable patients with metastatic or locally advanced solid tumors who failed to respond to standard therapy if available in the first part of an open-label, dose-escalation, U.S. Phase I trial showed that...
BioCentury | Sep 15, 2014
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 9/12cls BioDelivery Sciences International Inc. (NASDAQ:BDSI) Summer Street Jim Molloy Price target Buy 11% $18.15 Molloy raised his target to...
BC Week In Review | Dec 23, 2013
Clinical News

EC1456: Phase I started

Endocyte began an open-label, dose-escalation, U.S. Phase I trial to evaluate EC1456 in about 70 patients. The first part will evaluate the MTD and recommended Phase II dose in about 30 patients with metastatic or...
BioCentury | Sep 23, 2013
Emerging Company Profile

Tube: Potent payloads

The potency of Tube Pharmaceuticals GmbH 's tubulysin toxin as a conjugate payload could allow the company to target resistant cancers. Tube is developing a polymer-tubulysin conjugate for solid tumors and has out-licensed the toxin...
Items per page:
1 - 5 of 5